GLSI: FLAMINGO-01 expands HLA testing as early data indicate 70-80% lower recurrence

What happened

FLAMINGO-01 is testing GLSI-100 in a broader HLA population, with interim analyses planned. Preliminary non-HLA-A*02 data showed 70-80% lower recurrence after initial immunization, and Phase IIb results showed 100% 5-year DFS in the treated subgroup completing immunization.

Confirmed

Global impact / market context

If broader HLA testing confirms the early recurrence reduction, GLSI-100 could reach more patients, widening the potential treated population and supporting future revenue. The 5-year DFS figure, meaning disease-free survival, comes from a treated subgroup, so it may not represent all patients.

Analyst inference

Investors weigh early, small subgroup data cautiously because broader HLA enrollment may dilute or confirm the effect. Positive interim analyses could support capital spending on later trials, while mixed results could raise costs and delay progress, shaping positioning in Greenwich Lifesciences shares.

Analyst inference

What to watch

1. Interim analyses from FLAMINGO-01 are planned, and their timing and results will show whether the early 70-80% lower recurrence holds in the broadened HLA population. Confirmed
2. Watch whether Greenwich Lifesciences expands HLA testing further or adds trial sites, which would raise capital spending and could signal confidence in GLSI-100's broader use. Proposed
3. Track the treated subgroup completing immunization, since its 100% 5-year DFS, meaning disease-free survival, may not carry over to the full trial population. Analyst inference

Evidence

• Original source link unavailable